Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations (G12V or G12D). The treatment involves collecting a patient's own immune cells, engineering them to recognize and attack cancer cells carrying the muta…
Phase: PHASE1 • Sponsor: Ting Deng • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC